

ABSTRACT

A pharmaceutical composition for the treatment of cancer of which survival and/or metastasis is under the influence of signal transduction mediated by a chemokine receptor CXCR3, which comprises an agent to
5 inhibit CXCR3, and a method of treatment and diagnosis of such cancer.